Thrombomodulin expression regulates tumorigenesis in bladder cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Wu, Chun Te ^a,b   Chang, Ying Hsu ^a,b   Lin, Paul Y ^a,b   Chen, Wen Cheng ^a,b   Chen, Miao Fen ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Bladder cancer; DNMT1; Epithelial mesenchymal transition (EMT); Thrombomodulin

Indexed keywords

CAFFEIC ACID PHENETHYL ESTER; DNA METHYLTRANSFERASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; THROMBOMODULIN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER GROWTH; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PREDICTIVE VALUE; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; TUMOR INVASION; TUMOR VASCULARIZATION; ANIMAL; BIOSYNTHESIS; BLADDER TUMOR; CARCINOGENESIS; CELL TRANSFORMATION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NF-KAPPA B; PROGNOSIS; THROMBOMODULIN; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902178629     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-375     Document Type: Article

References (43)

1. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B. Focus on bladder cancer. Cancer Cell 2004, 6:111-116. 10.1016/j.ccr.2004.08.002, 15324694.
2. Amling CL. Diagnosis and management of superficial bladder cancer. Curr Probl Cancer 2001, 25:219-278.
3. Abogunrin F, OKane HF, Ruddock MW, Stevenson M, Reid CN, OSullivan JM, Anderson NH, ORourke D, Duggan B, Lamont JV, Boyd RE, Hamilton P, Nambirajan T, Williamson KE. The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria. Cancer 2012, 118:2641-2650. 10.1002/cncr.26544, 21918968.
4. Esmon CT. The regulation of natural anticoagulant pathways. Science 1987, 235:1348-1352. 10.1126/science.3029867, 3029867.
5. Kao YC, Wu LW, Shi CS, Chu CH, Huang CW, Kuo CP, Sheu HM, Shi GY, Wu HL. Downregulation of thrombomodulin, a novel target of Snail, induces tumorigenesis through epithelial-mesenchymal transition. Mol Cell Biol 2010, 30:4767-4785. 10.1128/MCB.01021-09, 2950553, 20713448.
6. ten Cate H, Falanga A. Overview of the postulated mechanisms linking cancer and thrombosis. Pathophysiol Haemost Thromb 2008, 36:122-130.
7. Horowitz NA, Palumbo JS. Mechanisms coupling thrombomodulin to tumor dissemination. Thromb Res 2012, 129(Suppl 1):S119-S121.
8. Zhang Y, Weiler-Guettler H, Chen J, Wilhelm O, Deng Y, Qiu F, Nakagawa K, Klevesath M, Wilhelm S, Böhrer H, Nakagawa M, Graeff H, Martin E, Stern DM, Rosenberg RD, Ziegler R, Nawroth PP. Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity. J Clin Invest 1998, 101:1301-1309. 10.1172/JCI925, 508707, 9525972.
9. Koutsi A, Papapanagiotou A, Papavassiliou AG. Thrombomodulin: from haemostasis to inflammation and tumourigenesis. Int J Biochem Cell Biol 2008, 40:1669-1673. 10.1016/j.biocel.2007.06.024, 17709273.
10. Ogawa H, Yonezawa S, Maruyama I, Matsushita Y, Tezuka Y, Toyoyama H, Yanagi M, Matsumoto H, Nishijima H, Shimotakahara T, Aikou T, Sato E. Expression of thrombomodulin in squamous cell carcinoma of the lung: its relationship to lymph node metastasis and prognosis of the patients. Cancer Lett 2000, 149:95-103. 10.1016/S0304-3835(99)00348-1, 10737713.
11. Hanly AM, Redmond M, Winter DC, Brophy S, Deasy JM, Bouchier-Hayes DJ, Kay EW. Thrombomodulin expression in colorectal carcinoma is protective and correlates with survival. Br J Cancer 2006, 94:1320-1325. 10.1038/sj.bjc.6603098, 2361416, 16622452.
12. Hanly AM, Hayanga A, Winter DC, Bouchier-Hayes DJ. Thrombomodulin: tumour biology and prognostic implications. Eur J Surg Oncol 2005, 31:217-220. 10.1016/j.ejso.2004.11.017, 15780553.
13. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002, 420:860-867. 10.1038/nature01322, 2803035, 12490959.
14. Gonda TA, Tu S, Wang TC. Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle 2009, 8:2005-2013. 10.4161/cc.8.13.8985, 19550141.
15. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004, 202:275-293. 10.1111/j.0105-2896.2004.00199.x, 15546400.
16. Zhu Z, Shen Z, Xu C. Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer. Mediators Inflamm 2012, 2012:528690. doi: 10.1155/2012/528690, 3395159, 22811589.
17. Ordonez NG. Thrombomodulin expression in transitional cell carcinoma. Am J Clin Pathol 1998, 110:385-390.
18. Ordonez NG. Value of thrombomodulin immunostaining in the diagnosis of transitional cell carcinoma: a comparative study with carcinoembryonic antigen. Histopathology 1997, 31:517-524. 10.1046/j.1365-2559.1997.3040892.x, 9447382.
19. Weiler H, Lindner V, Kerlin B, Isermann BH, Hendrickson SB, Cooley BC, Meh DA, Mosesson MW, Shworak NW, Post MJ, Conway EM, Ulfman LH, von Andrian UH, Weitz JI. Characterization of a mouse model for thrombomodulin deficiency. Arterioscler Thromb Vasc Biol 2001, 21:1531-1537. 10.1161/hq0901.094496, 11557684.
20. Ikeguchi H, Maruyama S, Morita Y, Fujita Y, Kato T, Natori Y, Akatsu H, Campbell W, Okada N, Okada H, Yuzawa Y, Matsuo S. Effects of human soluble thrombomodulin on experimental glomerulonephritis. Kidney Int 2002, 61:490-501. 10.1046/j.1523-1755.2002.00160.x, 11849389.
21. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, Rade JJ. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood 2005, 105:3910-3917. 10.1182/blood-2004-03-0928, 15677570.
22. Kaneda A, Kaminishi M, Yanagihara K, Sugimura T, Ushijima T. Identification of silencing of nine genes in human gastric cancers. Cancer Res 2002, 62:6645-6650.
23. Wu CT, Wu CF, Lu CH, Lin CC, Chen WC, Lin PY, Chen MF. Expression and function role of DNA methyltransferase 1 in human bladder cancer. Cancer 2011, 117:5221-5233. 10.1002/cncr.26150, 21523767.
24. Chen MF, Lin PY, Wu CF, Chen WC, Wu CT. IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer. PLoS One 2013, 8(4):e61901. 10.1371/journal.pone.0061901, 3640078, 23637926.
25. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994, 12:141-179. 10.1146/annurev.iy.12.040194.001041, 8011280.
26. Lin Y, Bai L, Chen W, Xu S. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets 2010, 14:45-55. 10.1517/14728220903431069, 3043547, 20001209.
27. Levidou G, Saetta AA, Korkolopoulou P, Papanastasiou P, Gioti K, Pavlopoulos P, Diamantopoulou K, Thomas-Tsagli E, Xiromeritis K, Patsouris E. Clinical significance of nuclear factor (NF)-kappaB levels in urothelial carcinoma of the urinary bladder. Virchows Arch 2008, 452:295-304. 10.1007/s00428-007-0560-y, 18188593.
28. Rothwarf DM, Karin M. The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE 1999, 1999(5):RE1.
29. Wu CS, Chen MF, Lee IL, Tung SY. Predictive role of nuclear factor-kappaB activity in gastric cancer: a promising adjuvant approach with caffeic acid phenethyl ester. J Clin Gastroenterol 2007, 41:894-900. 10.1097/MCG.0b013e31804c707c, 18090157.
30. Chen MF, Lu MS, Chen PT, Chen WC, Lin PY, Lee KD. Role of interleukin 1 beta in esophageal squamous cell carcinoma. J Mol Med (Berl) 2012, 90:89-100. 10.1007/s00109-011-0809-4, 21912958.
31. Baumgart E, Cohen MS, Silva Neto B, Jacobs MA, Wotkowicz C, Rieger-Christ KM, Biolo A, Zeheb R, Loda M, Libertino JA, Summerhayes IC. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res 2007, 13:1685-1694. 10.1158/1078-0432.CCR-06-2330, 17363521.
32. McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, Siefker-Radtke A, Dinney C. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 2009, 28:335-344. 10.1007/s10555-009-9194-7, 20012924.
33. Honn KV, Tang DG. Adhesion molecules and tumor cell interaction with endothelium and subendothelial matrix. Cancer Metastasis Rev 1992, 11:353-375. 10.1007/BF01307187, 1423822.
34. Becker KF, Rosivatz E, Blechschmidt K, Kremmer E, Sarbia M, Höfler H. Analysis of the E-cadherin repressor Snail in primary human cancers. Cells Tissues Organs 2007, 185:204-212. 10.1159/000101321, 17587826.
35. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000, 2:76-83. 10.1038/35000025, 10655586.
36. Nakanishi R, Oka N, Nakatsuji H, Koizumi T, Sakaki M, Takahashi M, Fukumori T, Kanayama HO. Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer. Urol Int 2009, 83:98-106. 10.1159/000224877, 19641368.
37. Reis ST, Leite KR, Piovesan LF, Pontes-Junior J, Viana NI, Abe DK, Crippa A, Moura CM, Adonias SP, Srougi M, DallOglio MF. Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer. BMC Urol 2012, 12:18. 10.1186/1471-2490-12-18, 3424138, 22695075.
38. Sharma S, Sharma MC, Sarkar C. Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology 2005, 46:481-489. 10.1111/j.1365-2559.2005.02142.x, 15842629.
39. Horowitz NA, Blevins EA, Miller WM, Perry AR, Talmage KE, Mullins ES, Flick MJ, Queiroz KC, Shi K, Spek CA, Conway EM, Monia BP, Weiler H, Degen JL, Palumbo JS. Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. Blood 2011, 118:2889-2895. 10.1182/blood-2011-03-341222, 3172805, 21788337.
40. Nocchi L, Tomasetti M, Amati M, Neuzil J, Santarelli L, Saccucci F. Thrombomodulin is silenced in malignant mesothelioma by a poly(ADP-ribose) polymerase-1-mediated epigenetic mechanism. J Biol Chem 2011, 286:19478-19488. 10.1074/jbc.M110.217331, 3103327, 21489980.
41. Menschikowski M, Hagelgans A, Tiebel O, Vogel M, Eisenhofer G, Siegert G. Regulation of thrombomodulin expression in prostate cancer cells. Cancer Lett 2012, 322:177-184. 10.1016/j.canlet.2012.03.001, 22406829.
42. Natarajan K, Singh S, Burke TR, Grunberger D, Aggarwal BB. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci U S A 1996, 93:9090-9095. 10.1073/pnas.93.17.9090, 38600, 8799159.
43. Wu J, Omene C, Karkoszka J, Bosland M, Eckard J, Klein CB, Frenkel K. Caffeic acid phenethyl ester (CAPE), derived from a honeybee product propolis, exhibits a diversity of anti-tumor effects in pre-clinical models of human breast cancer. Cancer Lett 2011, 308:43-53. 10.1016/j.canlet.2011.04.012, 3144783, 21570765.